 |
|
Chronic Urticaria and Monoclonal IgM Gammopathy (Schnitzler Syndrome)Report of 11 Cases Treated With Pefloxacin
Bouchra Asli, MD;
Boris Bienvenu, MD;
Florence Cordoliani, MD;
Jean-Claude Brouet, MD, PhD;
Yurdagul Uzunhan, MD;
Bertrand Arnulf, MD;
Marion Malphettes, MD;
Michel Rybojad, MD;
Jean-Paul Fermand, MD
Arch Dermatol. 2007;143(8):1046-1050.
Background Schnitzler syndrome is characterized by chronic urticarial rash and monoclonal IgM gammopathy and is sometimes associated with periodic fever, arthralgias, and bone pain. Current treatment is unsatisfactory.
Observations Eleven patients with Schnitzler syndrome were treated with oral pefloxacin mesylate (800 mg/d). In 10 patients, we observed a dramatic and sustained improvement of urticarial and systemic manifestations. Corticosteroid therapy could be stopped or reduced in 6 patients. In 9 patients, pefloxacin was administered for more than 6 months ( 10 years), with a good safety profile.
Conclusions Pefloxacin therapy can be considered for patients with Schnitzler syndrome because it usually improves chronic urticaria and the systemic symptoms of the disease.
Author Affiliations: Service d’Immunohématologie (Drs Asli, Brouet, Arnulf, Malphettes, and Fermand) and Service de Dermatologie (Drs Cordoliani and Rybojad), Hôpital Saint Louis, and Service de Médecine Interne, Hôpital Cochin (Dr Bienvenu), Paris, France.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Chronic Urticaria and Arthritis with Polyclonal IgA: Rapid Response and Clinical Remission with Interleukin 1 Blockade
CHU
The Journal of Rheumatology 2010;37:881-882.
FULL TEXT
|
